Cargando…
Effects of treatment of non-alcoholic fatty liver disease on heart failure with preserved ejection fraction
In the past few decades, non-alcoholic fatty liver disease (NAFLD) and heart failure with preserved ejection fraction (HFpEF) have become the most common chronic liver disease and the main form of heart failure (HF), respectively. NAFLD is closely associated with HFpEF by sharing common risk factors...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9877359/ https://www.ncbi.nlm.nih.gov/pubmed/36712249 http://dx.doi.org/10.3389/fcvm.2022.1120085 |
_version_ | 1784878350849802240 |
---|---|
author | Yang, Zifeng Tian, Ruifeng Zhang, Xiao-Jing Cai, Jingjing She, Zhi-Gang Li, Hongliang |
author_facet | Yang, Zifeng Tian, Ruifeng Zhang, Xiao-Jing Cai, Jingjing She, Zhi-Gang Li, Hongliang |
author_sort | Yang, Zifeng |
collection | PubMed |
description | In the past few decades, non-alcoholic fatty liver disease (NAFLD) and heart failure with preserved ejection fraction (HFpEF) have become the most common chronic liver disease and the main form of heart failure (HF), respectively. NAFLD is closely associated with HFpEF by sharing common risk factors and/or by boosting systemic inflammation, releasing other secretory factors, and having an expansion of epicardial adipose tissue (EAT). Therefore, the treatments of NAFLD may also affect the development and prognosis of HFpEF. However, no specific drugs for NAFLD have been approved by the Food and Drug Administration (FDA) and some non-specific treatments for NAFLD are applied in the clinic. Currently, the treatments of NAFLD can be divided into non-pharmacological and pharmacological treatments. Non-pharmacological treatments mainly include dietary intervention, weight loss by exercise, caloric restriction, and bariatric surgery. Pharmacological treatments mainly include administering statins, thiazolidinediones, glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter 2 inhibitors, and metformin. This review will mainly focus on analyzing how these treatments may affect the development and prognosis of HFpEF. |
format | Online Article Text |
id | pubmed-9877359 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-98773592023-01-27 Effects of treatment of non-alcoholic fatty liver disease on heart failure with preserved ejection fraction Yang, Zifeng Tian, Ruifeng Zhang, Xiao-Jing Cai, Jingjing She, Zhi-Gang Li, Hongliang Front Cardiovasc Med Cardiovascular Medicine In the past few decades, non-alcoholic fatty liver disease (NAFLD) and heart failure with preserved ejection fraction (HFpEF) have become the most common chronic liver disease and the main form of heart failure (HF), respectively. NAFLD is closely associated with HFpEF by sharing common risk factors and/or by boosting systemic inflammation, releasing other secretory factors, and having an expansion of epicardial adipose tissue (EAT). Therefore, the treatments of NAFLD may also affect the development and prognosis of HFpEF. However, no specific drugs for NAFLD have been approved by the Food and Drug Administration (FDA) and some non-specific treatments for NAFLD are applied in the clinic. Currently, the treatments of NAFLD can be divided into non-pharmacological and pharmacological treatments. Non-pharmacological treatments mainly include dietary intervention, weight loss by exercise, caloric restriction, and bariatric surgery. Pharmacological treatments mainly include administering statins, thiazolidinediones, glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter 2 inhibitors, and metformin. This review will mainly focus on analyzing how these treatments may affect the development and prognosis of HFpEF. Frontiers Media S.A. 2023-01-12 /pmc/articles/PMC9877359/ /pubmed/36712249 http://dx.doi.org/10.3389/fcvm.2022.1120085 Text en Copyright © 2023 Yang, Tian, Zhang, Cai, She and Li. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cardiovascular Medicine Yang, Zifeng Tian, Ruifeng Zhang, Xiao-Jing Cai, Jingjing She, Zhi-Gang Li, Hongliang Effects of treatment of non-alcoholic fatty liver disease on heart failure with preserved ejection fraction |
title | Effects of treatment of non-alcoholic fatty liver disease on heart failure with preserved ejection fraction |
title_full | Effects of treatment of non-alcoholic fatty liver disease on heart failure with preserved ejection fraction |
title_fullStr | Effects of treatment of non-alcoholic fatty liver disease on heart failure with preserved ejection fraction |
title_full_unstemmed | Effects of treatment of non-alcoholic fatty liver disease on heart failure with preserved ejection fraction |
title_short | Effects of treatment of non-alcoholic fatty liver disease on heart failure with preserved ejection fraction |
title_sort | effects of treatment of non-alcoholic fatty liver disease on heart failure with preserved ejection fraction |
topic | Cardiovascular Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9877359/ https://www.ncbi.nlm.nih.gov/pubmed/36712249 http://dx.doi.org/10.3389/fcvm.2022.1120085 |
work_keys_str_mv | AT yangzifeng effectsoftreatmentofnonalcoholicfattyliverdiseaseonheartfailurewithpreservedejectionfraction AT tianruifeng effectsoftreatmentofnonalcoholicfattyliverdiseaseonheartfailurewithpreservedejectionfraction AT zhangxiaojing effectsoftreatmentofnonalcoholicfattyliverdiseaseonheartfailurewithpreservedejectionfraction AT caijingjing effectsoftreatmentofnonalcoholicfattyliverdiseaseonheartfailurewithpreservedejectionfraction AT shezhigang effectsoftreatmentofnonalcoholicfattyliverdiseaseonheartfailurewithpreservedejectionfraction AT lihongliang effectsoftreatmentofnonalcoholicfattyliverdiseaseonheartfailurewithpreservedejectionfraction |